tofacitinib for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
STOP-COVID (Guimarães) NCT04469114		RCT	tofacitinib	placebo	COVID 19 hospitalized	low	144/145	conclusif	demonstrated 37 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
COVID-19 mild to moderate meta-analysis
Murugesan		RCT	tofacitinib	standard of care	COVID-19 mild to moderate	NA	50/50	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis